ENBREL (etanercept), TNF inhibitor

RHEUMATOLOGY - New indication
Opinions on drugs - Posted on Nov 12 2015 - Updated on Mar 17 2016

Reason for request

Extension of indication

No clinical benefit demonstrated by comparison with HUMIRA (adalimumab) or CIMZIA (certolizumab pergol) in the management of patients with severe non-radiographic axial spondyloarthritis with objective signs of inflammation on the failure of NSAIDs.


  • ENBREL now has Marketing Authorisation in the treatment of severe non-radiographic axial spondyloarthritis in adults with objectives signs of inflammation, taking the form of an elevated level of C-reactive protein (CRP) and/or signs visible in magnetic resonance imaging (MRI), in patients with an inadequate response to non-steroidal antiinflammatories (NSAIDs).
  • Since no comparison is available with other TNF inhibitors indicated in non-radiographic axial spondyloarthritis, it is not possible to rank them.


Clinical Benefit



Clinical Added Value

no clinical added value


Therapeutic use


Contact Us

Évaluation des médicaments